Both RNA interference-mediated silencing and CRISPR-mediated gene editing deletion of NRP1 strongly impair the invasive capacity of properties of patient-derived GBM BTSCs and their close localization to brain blood vessels without affecting BTSC expansion and self-renewal. This evidence concerns the gene NRP1 and glioblastoma.